First Tracks Biotherapeutics, Inc. Form 8-K — Oct 15, 2026
Form 8-KItems 1.01, 3.02, 7.01, 9.01Filed Oct 15, 2026, 4:28 PM ET0001193125-26-422929Original filing
First Tracks Biotherapeutics (Nasdaq: TRAX) entered a securities purchase agreement on October 15, 2026 to sell 6,106,870 shares at $32.75 per share in a private placement for approximately $200 million in gross proceeds. The offering represents roughly 17% dilution against the 35,909,814 shares outstanding as of October 12, 2026, and closing is expected October 19, 2026 with a minimum closing condition of $110 million.
Key figures
- Gross Proceeds
- 200000000
- Offering Price
- 32.75
- Shares Offered
- 6106870
- Shares Outstanding
- 35909814
- Closing Date
- 2026-10-19
- Dilution Percent
- approximately 17%
- Liquidated Damages Rate
- 1.0% per 30-day period, capped at 5.0%
- Minimum Closing Proceeds
- 110000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.